Infection in solid-organ transplant recipients

New England Journal of Medicine

Volumn 357, Issue 25, 2007, Pages 2601-2614

  Fishman, Jay A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATOVAQUONE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CIDOFOVIR; CORTICOSTEROID; COTRIMOXAZOLE; CYTOKINE; DAPSONE; FLUCONAZOLE; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; INTERFERON; LEFLUNOMIDE; METICILLIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; PNEUMOCOCCUS VACCINE; RAPAMYCIN; VALGANCICLOVIR; VANCOMYCIN;

ALGORITHM; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ASSAY; BACTEREMIA; BACTERIAL INFECTION; BK VIRUS; CANDIDA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CHAGAS DISEASE; CLINICAL ASSESSMENT; CLINICAL LABORATORY; CLINICAL PRACTICE; COCCIDIOIDES IMMITIS; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCUS NEOFORMANS; CYTOKINE RELEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; DRUG MEGADOSE; ENTEROCOCCUS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; GENOMICS; GRAFT REJECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMA CAPSULATUM; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION RISK; JC VIRUS; LABORATORY TEST; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG TRANSPLANTATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOPROLIFERATIVE DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; ORGAN DONOR; ORGAN TRANSPLANTATION; PARACOCCIDIOIDES BRASILIENSIS; PATIENT MONITORING; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; POLYOMA VIRUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RABIES; REVIEW; SCREENING TEST; SEXUALLY TRANSMITTED DISEASE; STRONGYLOIDES STERCORALIS; THORAX RADIOGRAPHY; TRYPANOSOMA CRUZI; TUBERCULOSIS; VACCINATION; VARICELLA ZOSTER VIRUS; VIREMIA; VIRUS ENCEPHALITIS; VIRUS INFECTION; VIRUS LOAD; WEST NILE FLAVIVIRUS;

EID: 37349073878     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra064928     Document Type: Article

References (105)

1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-51.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-29.
3. Wilck M, Fishman J. The challenges of infection in transplantation: donor-derived infections. Curr Opin Organ Transplant 2005;10:301-6.
4. Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl 2003;9:451-62.
5. Delmonico FL. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 2000;31:781-6.
6. Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999;68:1107-11.
7. Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006;354:2235-49.
8. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003;348:2196-203.
9. Srinivasan A, Burton EC, Kuehnert MJ, et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005;352:1103-11.
10. Chagas disease after organ transplantation - United States, 200MMWR Morb Mortal Wkly Rep 2002;51:210-2.
11. Preiksaitis JK, Green M, Avery RK. Guidelines for the prevention and managment of infectious complications of solid organ transplantation. Am J Transplant 2004;4:Suppl 10:51-8.
12. D'Albuquerque LA, Gonzalez AM, Filho HL, et al. Liver transplantation from deceased donors serologically positive for Chagas disease. Am J Transplant 2007;7:680-4.
13. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999;29:1220-6. [Erratum, Hepatology 1999;30:1110.]
14. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-22.
15. Chazouilleres O, Wright TL. Hepatitis C and liver transplantation. J Gastroenterol Hepatol 1995;10:471-80.
16. Fishman JA, Rubin RH, Koziel MJ, Periera BJ. Hepatitis C virus and organ transplantation. Transplantation 1996;62:147-54.
17. Seehofer D, Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation 2005;80:Suppl 1:S120-S124.
18. Trautwein C. Mechanisms of hepatitis B virus graft reinfection and graft damage after liver transplantation. J Hepatol 2004;41:362-9.
19. Basset D, Faraut F, Marty P, et al. Visceral leishmaniasis in organ transplant recipients: 11 new cases and a review of the literature. Microbes Infect 2005;7:1370-5.
20. Boletis JN, Pefanis A, Stathakis C, Helioti H, Kostakis A, Giamarellou H. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome). Clin Infect Dis 1999;28:1308-9.
21. Frapier JM, Abraham B, Dereure J, Albat B. Fatal visceral leishmaniasis in a heart transplant recipient. J Heart Lung Transplant 2001;20:912-3.
22. Gómez Campderá F, Berenguer J, Anaya F, Rodriguez M, Valderrábano F. Visceral leishmaniasis in a renal transplant recipient: short review and therapy alternative. Am J Nephrol 1998;18:171.
23. Portolés J, Prats D, Torralbo A, Herrero JA, Torrente J, Barrientos A. Visceral leishmaniasis: a cause of opportunistic infection in renal transplant patients in endemic areas. Transplantation 1994;57:1677-9.
24. Scoggin CH, Call NB. Acute respiratory failure due to disseminated strongyloidiasis in a renal transplant recipient. Ann Intern Med 1977;87:456-8.
25. Palau LA, Pankey GA. Strongyloides hyperinfection in a renal transplant recipient receiving cyclosporine: possible Strongyloides stercoralis transmission by kidney transplant. Am J Trop Med Hyg 1997;57:413-5.
26. Fishman JA. Transplantation for patients infected with human immunodeficiency virus: no longer experimental but not yet routine. J Infect Dis 2003;188:1405-11.
27. Roland ME, Stock PG. Review of solidorgan transplantation in HIV-infected patients. Transplantation 2003;75:425-9.
28. Fung J, Eghtesad B, Patel-Tom K, De-Vera M, Chapman H, Ragni M. Liver transplantation in patients with HIV infection. Liver Transpl 2004;10:Suppl 2:S39-S53.
29. Moreno S, Fortún J, Quereda C, et al. Liver transplantation in HIV-infected recipients. Liver Transpl 2005;11:76-81.
30. Lake JR. Immunosuppression and outcomes of patients transplanted for hepatitis C. J Hepatol 2006;44:627-9.
31. Pastore M, Willems M, Cornu C, et al. Role of hepatitis C virus in chronic liver disease occurring after orthotopic liver transplantation. Arch Dis Child 1995;72:403-7.
32. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004;78:955-63.
33. Muñoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002;8:Suppl 1:S82-S87.
34. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003;9:S63-S66.
35. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002;346:867-9.
36. Patel R, Rouse MS, Piper KE, Steckelberg JM. Linezolid therapy of vancomycin-resistant Enterococcus faecium experimental endocarditis. Antimicrob Agents Chemother 2001;45:621-3.
37. Fishman JA. Vancomycin-resistant Enterococcus in liver transplantation: what have we left behind? Transpl Infect Dis 2003;5:109-11.
38. Keven K, Basu A, Re L, et al. Clostridium difficile colitis in patients after kidney and pancreas-kidney transplantation. Transpl Infect Dis 2004;6:10-4.
39. West M, Pirenne J, Chavers B, et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant 1999;13:318-23.
40. Muder RR, Stout JE, Yu VL. Nosocomial Legionella micdadei infection in transplant patients: fortune favors the prepared mind. Am J Med 2000;108:346-8.
41. Lo Presti F, Riffard S, Vandenesch F, et al. The first clinical isolate of Legionella parisiensis, from a liver transplant patient with pneumonia. J Clin Microbiol 1997;35:1706-9.
42. Harbarth S, Pittet D, Romand J. Fatal concomitant nosocomial Legionnaires' disease and cytomegalovirus pneumonitis after cardiac transplantation. Intensive Care Med 1996;22:1133-4.
43. Bert F, Bellier C, Lassel L, et al. Risk factors for Staphylococcus aureus infection in liver transplant recipients. Liver Transpl 2005;11:1093-9.
44. Zeevi A, Britz JA, Bentlejewski CA, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 2005;15:17-24.
45. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. Am J Med 1981;70:405-11.
46. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991;324:1057-9.
47. Avery RK. Prophylactic strategies before solid-organ transplantation. Curr Opin Infect Dis 2004;17:353-6.
48. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005;16:1758-74.
49. Kumar D, Welsh B, Siegal D, Hong Chen M, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients - three year follow-up of a randomized trial. Am J Transplant 2007;7:633-8.
50. Pappas PG, Andes D, Schuster M, et al. Invasive fungal infections in low-risk liver transplant recipients: a multi-center prospective observational study. Am J Transplant 2006;6:386-91.
51. Dummer JS, Lazariashvilli N, Barnes J, Ninan M, Milstone AP. A survey of antifungal management in lung transplantation. J Heart Lung Transplant 2004;23:1376-81.
52. Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003;37:221-9.
53. Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am 2003;17:113-34.
54. George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med 1997;103:106-13.
55. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996;62:926-34.
56. Karchmer AW, Samore MH, Hadley S, Collins LA, Jenkins RL, Lewis WD. Fungal infections complicating orthotopic liver transplantation. Trans Am Clin Climatol Assoc 1994;106:38-48.
57. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004;17:770-82.
58. Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000;2:112-7.
59. Migueles SA, Tilton JC, Connors M. Advances in understanding immunologic control of HIV infection. Curr HIV/AIDS Rep 2004;1(1):12-7.
60. Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000;343:225-6.
61. Cheeseman SH, Henle W, Rubin RH, et al. Epstein-Barr virus infection in renal transplant recipients: effects of antithymocyte globulin and interferon. Ann Intern Med 1980;93:39-42.
62. Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 1983;308:307-13.
63. Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russell PS, Hirsch MS. Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977;24:458-64.
64. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989;261:3607-9.
65. Sester M, Gärtner BC, Sester U, Girndt M, Mueller-Lantzsch N, Köhler H. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 2003;76:1229-30.
66. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R-transplant recipients. Am J Transplant 2005;5:1065-70.
67. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-80.
68. Strippoli GF, Hodson EM, Jones CJ, Craig JC. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2006;1:CD005133.
69. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365:2105-15.
70. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 1996;23:468-74.
71. Wagner JA, Ross H, Hunt S, et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995;60:1473-7.
72. Munoz-Price LS, Slifkin M, Ruthazer R, et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004;39:1293-9.
73. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003;10:60-5.
74. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004;4:1219-26.
75. Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003;75:2064-8.
76. Kirklin JK, Naftel DC, Levine TB, et al. Cytomegalovirus after heart transplantation: risk factors for infection and death: a multiinstitutional study. J Heart Lung Transplant 1994;13:394-404.
77. Valantine HA, Gao SZ, Menon SG, et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999;100:61-6.
78. Kalil RS, Hudson SL, Gaston RS. Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus? Am J Transplant 2003;3:79-81.
79. Humar A, Payne WD, Sutherland DE, Matas AJ. Clinical determinants of multiple acute rejection episodes in kidney transplant recipients. Transplantation 2000;69:2357-60.
80. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 1997;350:1729-33. [Erratum, Lancet 1998;351:454.]
81. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005;5:218-27. [Erratum, Am J Transplant 2005;5:635.]
82. Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999;68:1272-9.
83. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin Infect Dis 2002;34:1337-41. [Erratum, Clin Infect Dis 2006;42:1350.]
84. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005;7:166-70. [Erratum, Transpl Infect Dis 2006;8:58.]
85. Luan FL, Chopra P, Park J, Norman S, Cibrik D, Ojo A. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients. Transplant Proc 2006;38:3673-5.
86. Humar A, Siegal D, Moussa G, Kumar D. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients. J Infect Dis 2005;192:1154-7.
87. Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 2001;33:Suppl 1:S38-S46.
88. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001;71:1065-8.
89. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders: ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517-25.
90. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997;14:8-14.
91. Newell KA, Alonso EM, Whitington PF, et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation: interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996;62:370-5.
92. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A - prednisone immunosuppression. Am J Pathol 1988;133:173-92.
93. Rowe DT, Qu L, Reyes J, et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997;35:1612-5.
94. Green M, Webber SA. EBV viral load monitoring: unanswered questions. Am J Transplant 2002;2:894-5.
95. Fishman JA. BK virus nephropathy - polyomavirus adding insult to injury. N Engl J Med 2002;347:527-30.
96. Drachenberg CB, Papadimitriou JC, Wali R, Cubitt CL, Ramos E. BK polyoma virus allograft nephropathy: ultrastructural features from viral cell entry to lysis. Am J Transplant 2003;3:1383-92.
97. Vats A, Randhawa PS, Shapiro R. Diagnosis and treatment of BK virus-associated transplant nephropathy. Adv Exp Med Biol 2006;577:213-27.
98. Hirsch HH, Suthanthiran M. The natural history, risk factors and outcomes of polyomavirus BK-associated nephropathy after renal transplantation. Nat Clin Pract Nephrol 2006;2:240-1.
99. Hirsch HH, Drachenberg CB, Steiger J, Ramos E. Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management. Adv Exp Med Biol 2006;577:160-73.
100. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998;42:995-1004.
101. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003;111:1887-95.
102. Williams MA, Onami TM, Adams AB, et al. Cutting edge: persistent viral infection prevents tolerance induction and escapes immune control following CD28/CD40 blockade-based regimen. J Immunol 2002;169:5387-91.
103. Jenner RG, Young RA. Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol 2005;3:281-94.
104. Wang D, Coscoy L, Zylberberg M, et al. Microarray-based detection and genotyping of viral pathogens. Proc Natl Acad Sci U S A 2002;99:15687-92.
105. Sarwal MM. Chipping into the human genome: novel insights for transplantation. Immunol Rev 2006;210:138-55.